Chronic antigenic stimulation is frequently blamed in the pathogenesis of extranodal marginal zone lymphomas including splenic marginal zone lymphoma (SMZL). Chronic hepatitis C is frequently observed in SMZL patients in some geographical regions. However, these reports are largely from North America and Europe. Data from other countries are u n c o r r e c t e d p r o o f
insufficient. In this multicenter study we aimed to find out the clinical characteristics of SMZL patients in Turkey, including viral hepatitis status and treatment details.
Materials and Methods
Data were gathered from voluntary centers from different regions of Turkey using an IBM SPSS Statistics for Windows v23 electronic table.
Results
One hundred and four patients were reported. Hepatitis C virus positivity was observed in only one patient. However, hepatitis B virus surface antigen (HBsAg) positivity was observed in 11.2% and HBsAg and/or anti-HB core antigen antibody (anti-HBcAg) positivities in 34.2% of the patients. The median age was 60 years (35 87). Median follow-up duration was 21.2 months (0.2 212) (23.2 months for surviving patients). Median OS was not reached. Estimated 3-year and 10-year survival rates were 84.8% and 68.9%, respectively. Older age, no splenectomy during follow-up, <90×10 3 /µl platelet count, lower albumin, higher lactate dehydrogenase, higher β2-microglobulin and HBsAg positivity were associated with increased risk of death. Only albumin remained significant in multivariable analysis.
Conclusion
These results indicate that hepatitis B virus may be a possible risk factor for SMZL in our population. It may also be an indirect prognostic factor. Keywords: Low grade lymphoma; Hepatitis B virus, Hepatitis C virus; Risk factors.
TÜRKİYE'DE SPLENİK MARJİNAL ZON LENFOMA; HEPATİT C VİRUS YERİNE HEPATİT B VİRÜSÜNÜN ETİYOLOJİK VE OLASI PROGNOSTİK FAKTÖR OLUŞU-ÇOK MERKEZLİ KOHORT ÇALIŞMASI

ÖZET Giriş
Splenik marjinal zon lenfoma'yı (SMZL) da içeren ekstranodal marjinal zon lenfomaların patogenezinde, kronik antijenik stimulasyon sorumlu olan mekanizmadır. Bazı coğrafik bölgelerde SMZL hastalarında kronik hepatit C sıklıkla gözlenir. Fakat bu çalışmalar sıklıkla kuzey Amerika ve Avrupa'dandır. Diğer ülkelerden veriler sınırlıdır. Bu çalışma ile Türkiye'deki SMZL hastalarının hepatit serolojisi durumları ve tedavi yöntemlerinin ortaya konulması amaçlanmıştır.
Materyal ve Metot
Türkiye'de farklı merkezlerden IBM SPSS Statistics for Windows v23 elektronik tablo kullanılarak veriler toplanmıştır. Hepatit B virüs yüzey antijeni (HBsAg), Anti-HBs antikor, Anti-HB kor antijen antikoru (anti-HBcAg), HB virüs yükü, Anti hepatit C virüs (HCV) antikoru, HCV virüs yükü sonuçları analiz edilmiştir.
Bulgular
Yüz dört hastanın verilerine ulaşılmıştır. Hepatit C virüs pozitifliği sadece 1 hastada tespit edilmiştir. Hepatit B virüs yüzey antijeni (HBsAg) pozitifliği %11.2, HBsAg ve/veya hepatit B kor antijen antikoru (anti-HBcAg) pozitifliği %34.2 oranında tespit edilmiştir. Ortanca yaş 60 yıl (35-87) olarak saptanmıştır. Ortanca izlem süresi 21.2 (0.2 212) ay (yaşayan hastalar için 23.2 ay) olarak bulunmuştur. Ortanca genel sağkalım (GS) süresine ulaşılamamıştır. Tahmini 3-yıl ve 10-yıl GS oranları %84.8 ve %68.9 olarak bulunmuştur. İleri yaş, splenektomi yapılmaması, <90×10 3 /µl platelet sayısı, hipoalbuminemi, laktat dehidrogenaz yüksekliği, β2-mikroglobulin yüksekliği ve HBsAg pozitifliği sağkalımla ilişkili faktörler olarak bulunmuştur. Çok değişkenli analizde, sadece albumin düşüklüğü istatistiksel olarak anlamlı saptanmıştır.
Sonuç
Bu çalışmanın sonuçlarına göre, toplumumuzda SMZL için hepatit B virüsü olası bir risk faktörü olabilir. Aynı zamanda indirek bir prognostik gösterge olabilir.
Anahtar kelimeler: Düşük dereceli lenfomalar; hepatit B virüs; hepatit C virüs; risk faktörleri
Introduction
Splenic marginal zone lymphoma (SMZL) is a rare B-cell lymphoma. It constitutes less than 2% of lymphoid neoplasms [1] . Majority of patients have an indolent course with median overall survival near 10 years [2, 3] .
Chronic hepatitis C is frequently observed in SMZL patients. However, these reports are largely from North America and Europe [4, 5] . Data from various countries with different hepatitis prevalence rates are lacking.
Many prognostic factors have been described for SMZL, such as leukocytosis, thrombocytopenia, elevated β2-microglobulin, anemia, elevated lactate dehydrogenase (LDH), decreased albumin, impaired performance status, advanced age, bone marrow involvement and histologic transformation [6] [7] [8] [9] [10] . Various clinical prognostic scores have been described, but no universally accepted risk stratification formula has been identified.
No curative treatment has been described for this indolent neoplastic disorder. Treatment is indicated in the case of symptomatic disease and/or significant cytopenia. Splenectomy, rituximab, rituximab plus single or multiagent chemotherapy regimens and recently ibrutinib and idelalisib has been reported to give high treatment success rates [11] . In this multicenter cohort study we aimed to find out the clinical characteristics of SMZL patients in Turkey including viral hepatitis status, treatment details and survival.
Patients and Methods
Data were gathered from voluntary centers from different regions of Turkey using an IBM SPSS Statistics for Windows v23 (Armonk, NY) electronic table. The diagnosis of SMZL, established by the local hematopathologist, was accepted. Diagnoses was based on widening of the white pulp, without predominant red pulp involvement and a wide immunohistochemical panel that helped rule out other low grade B cell lymphomas and clinicopathologic correlation. The neoplastic B cell population was immunophenotypically required to lack cyclinD1, CD10, Bcl-6, CD123, Annexin-1 and co-expression of CD5 and CD23. Central review at our department of pathology was not obligatory, but statistical evaluations were repeated in the group of cases (n=40) which were diagnosed in the primary research center, Hacettepe University Faculty of Medicine (HUFM). Also in case of atypical clinical presentation (e.g. presence of prominent lymphadenopathies in addition to splenomegaly), unexpected u n c o r r e c t e d p r o o f morphological and/or immunophenotypic findings the submitting center was contacted to confirm the diagnosis. Age, gender, main reasons for admission to hospital, leukocyte, lymphocyte, neutrophil counts, hemoglobin level, platelet, serum albumin, β2-microglobulin at diagnosis, CD5, CD10, CD20, CD23, CD7, CD103, surface Ig, cyclin D1, FMC7 results (immunohistochemical or flow cytometry), spleen size, bone marrow involvement, extranodal involvement site, ECOG performance status, hepatitis B virus surface antigen (HBsAg), Anti-HBs antibody, Anti-HB core antigen antibody (anti-HBc), HB viral load, Anti hepatitis C virus (HCV) antibody, HCV viral load results were analyzed. In addition, first treatment choice (watch-and-wait, splenectomy, chemoimmunotherapy, etc), treatment response and survival status were recorded. Treatment responses were defined as previously reported [12] ; 1) hematological improvement (after splenectomy): at least 50% improvement on the blood counts. 2) partial response: ≥50% improvement in spleen size, cytopenias and lymphadenopathies if present, and decrease in the level of marrow lymphoid infiltration. 3) complete response: resolution of organomegaly, normalization of the blood counts (hemoglobin > 12 g/dl, platelet count > 100×10 3 / l, neutrophil > 1.5×10 3 / l), no evidence of circulating clonal B cells and no or minor BM infiltration detected by immunohistochemistry. 4) no response or progressive disease: less than partial response or disease progression.
2.1.Statistical Analysis
Categorical and continuous data were expressed as ratio (%) and median (range) and they were compared by the chi-square and independent samples t tests, respectively. Survival analyses were computed by the Kaplan-Meier method. Overall survival (OS) was calculated from presentation to the date of mortality due to any reason. Patients who had not died at last follow-up were censored at this time. Parameters related to survival were investigated by Cox regression univariate and multivariate analyses. All 7 parameters (in table 2) were included in multivariable model. All patients gave informed consent about their treatment and information analyses. This study complied with the Declaration of Helsinki. IBM SPSS Statistics for Windows v23 was used for statistical analyses. P values <0.05 were considered statistically significant.
Results
One hundred four patients, diagnosed between June 1999 and November 2017, were reported from 23 hematology/ oncology centers. 47 cases (45%) were diagnosed/ confirmed at our center. Data on baseline clinical characteristics are presented in table 1. The median age was 60 years (35 87). 62.5% of the patients were female. Cytopenia(s) and/or related symptoms (26.8%) and abdominal discomfort (45.4%) were the most frequent reasons for hospital admission. 46.1% of patients had B symptoms (fever, night sweats, weight loss) at presentation. 8.6% of the patients lacked disease-related symptoms and were diagnosed incidentally. According to ECOG performance scoring; 22.1%, 47.4%, 23.2% and 7.4% of patients were scored 0, 1, 2, and 3, respectively. 77.9% and 49% of patients had bone marrow and peripheral blood involvement at diagnosis, respectively. 17.3% of patients had prominent lymphadenopathies in addition to splenomegaly. Wait-and-watch strategy, splenectomy, and chemo(immune)therapy were the upfront management methods in 18.4%, 49.5%, and 32.1% of patients, respectively. Only 79 patients were evaluated for response. Hematological improvement and complete response were provided in the majority of patients ( Table 2 .
Discussion
In this final analysis we report increased prevalence of chronic HBV infection in SMZL patients. HBV exposure is prevalent among adults in our country. The reported HBsAg positivity ratio in blood donors was approximately 2-3% during the last decade [13, 14] . In recent epidemiological data the prevalence was reported as close to 4% [15] . Anti-HCV positivity ratio was reported as close to 1% in our country [16] . HBsAg was 3.7% and anti-HCV Ab positivity was 2.8% in lymphoma patients, in the study from our country [17] . We have previously reported interim results of this study in 2016 [18] . To the best of our knowledge we were the first group to suggest a possible association between HBV and SMZL in a considerably large SMZL cohort. Some other studies had reported only on a few patients with SMZL associated with HBV [19] [20] [21] [22] [23] . Recently, Fetica et al. [24] from Romania found HBV infection in 3 patients out of 34 SMZL patients at the same time period with our early report. A more recent study from China reported HBsAg positivity in 25/ 160 (16%) and resolved HBV infection (HBs Ag negative, AntiHBc positive) in 54/ 160 (34%) patients [25] . Summary of the data in the literature on HBV and HCV seropositivity was shown in Table 3 [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] .
Chronic antigenic stimulation is frequently blamed in the pathogenesis of extranodal marginal zone lymphomas. The association between gastric mucosa-associated lymphoid tissue lymphoma and chronic helicobacter pylori infection is the classical example for this relationship. An association between HCV and SMZL has been previously reported in some geographic regions, mostly in Southern Europe [2, 5, 29] . Now we can suggest that the association between SMZL and chronic viral hepatitis is not specific for HCV. HBV may also be responsible from SMZL lymphomagenesis.
Splenectomy and rituximab-based chemoimmunotherapies were the most frequently used treatments in our cohort. This is in concordance with current treatment strategies for SMZL. Responses (most commonly hematological improvement after splenectomy as expected) were very frequent (94.9%) in our cohort. Median follow up duration (21.2 months) in our patients was relatively short for this indolent lymphoma. Estimated 10 year survival was u n c o r r e c t e d p r o o f 68.6%. We found many parameters (lower albumin, splenectomy, thrombocytopenia, elevated LDH, higher 2 microglobulin, and HBsAg positivity) to be associated with overall survival. But albumin was the only parameter to retain marginal significance in multivariate analysis (figure 2). HBsAg positivity was an adverse prognostic factor in univariate analysis, but not in the multivariate test. Possibly HBV may indirectly effect survival by lowering serum albumin level due to liver impairment. This suggestion should be investigated in further studies.
Arcaini et al [2] reported 10-year OS as 65% in SMZL. In this study the authors proposed a prognostic model including hemoglobin < 12 g/ dl, elevated LDH and albumin level < 3.5 g/ dl as adverse prognostic factors. In another study, Montalban et al [5] developed a continuous model for estimating lymphoma specific survival including decreased hemoglobin level, lower platelet count, elevated LDH, and extrahilar lymphadenopathy as unfavorable prognostic indicators. In the recent Chinese study [25] , the authors also suggested a new prognostic system. Decreased hemoglobin, HBsAg positivity and complex karyotype were related to decreased survival in this study. We did not intend to develop a prognostic scoring system or to test previously suggested scoring systems in this study. But it is convincing to observe that many of the risk factors we identified in univariate analyses have been previously reported to have prognostic significance in SMZL.
The major limitations of the study are its retrospective design and somewhat limited number of patients.
Our results in association with some recent literature data indicate that HBV may be a possible risk factor for development of SMZL in some geographical regions similar to HCV in some western countries. It may also be an indirect prognostic factor. Obviously larger studies about this rare lymphoma can provide better quality data and firmer conclusions on this relationship and the prognostic impact of HBV. 
